Home Healthcare Pharmaceuticals Gout Therapeutics Market

Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Xanthine Oxidase Inhibitors, NSAIDs, Corticosteroids, Uricosurics, Recombinant Uricase, Interleukin-1 Inhibitors, Others), By Disease Type (Acute, Intercritical, Chronic tophaceous, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Gout Therapeutics Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Xanthine Oxidase Inhibitors
    2. NSAIDs
    3. Corticosteroids
    4. Uricosurics
    5. Recombinant Uricase
    6. Interleukin-1 Inhibitors
    7. Others
  2. Gout Therapeutics Market, By Disease Type 2022-2034 (USD MILLION/ Units)
    1. Acute 
    2. Intercritical 
    3. Chronic tophaceous
    4. Others
  3. Gout Therapeutics Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Pharmacies
  4. Regional Gout Therapeutics Market
    1. North America
      1. North America Gout Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
      2. North America Gout Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Acute 
        2. Intercritical 
        3. Chronic tophaceous
        4. Others
      3. North America Gout Therapeutics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.S.
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Canada
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    2. Europe
      1. Europe Gout Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
      2. Europe Gout Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Acute 
        2. Intercritical 
        3. Chronic tophaceous
        4. Others
      3. Europe Gout Therapeutics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.K.
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Germany
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. France
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. Spain
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Italy
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Russia
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Nordic
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      11. Benelux
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      12. Rest of Europe
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    3. APAC
      1. APAC Gout Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
      2. APAC Gout Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Acute 
        2. Intercritical 
        3. Chronic tophaceous
        4. Others
      3. APAC Gout Therapeutics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. China
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Korea
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Japan
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. India
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Australia
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Taiwan
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. South East Asia
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      11. Rest of Asia-Pacific
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Gout Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
      2. Middle East and Africa Gout Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Acute 
        2. Intercritical 
        3. Chronic tophaceous
        4. Others
      3. Middle East and Africa Gout Therapeutics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. UAE
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Turkey
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Saudi Arabia
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. South Africa
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Egypt
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Nigeria
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      10. Rest of MEA
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
    5. LATAM
      1. LATAM Gout Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
      2. LATAM Gout Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Acute 
        2. Intercritical 
        3. Chronic tophaceous
        4. Others
      3. LATAM Gout Therapeutics Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. Brazil
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      5. Mexico
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      6. Argentina
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      7. Chile
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      8. Colombia
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
      9. Rest of LATAM
        1. Xanthine Oxidase Inhibitors
        2. NSAIDs
        3. Corticosteroids
        4. Uricosurics
        5. Recombinant Uricase
        6. Interleukin-1 Inhibitors
        7. Others
        8. Acute 
        9. Intercritical 
        10. Chronic tophaceous
        11. Others
        12. Hospital Pharmacies
        13. Drug Stores & Retail Pharmacies
        14. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.